company background image
LT4 logo

Liquidia BST:LT4 Stock Report

Last Price

€10.08

Market Cap

€854.9m

7D

0%

1Y

n/a

Updated

04 Nov, 2024

Data

Company Financials +

LT4 Stock Overview

A biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States.

LT4 fundamental analysis
Snowflake Score
Valuation2/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Liquidia Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Liquidia
Historical stock prices
Current Share PriceUS$10.08
52 Week HighUS$15.56
52 Week LowUS$6.75
Beta0.22
11 Month Change3.97%
3 Month Changen/a
1 Year Changen/a
33 Year Change180.62%
5 Year Change196.47%
Change since IPO-23.58%

Recent News & Updates

Recent updates

Shareholder Returns

LT4DE PharmaceuticalsDE Market
7D0%-1.8%-1.8%
1Yn/a-12.8%13.6%

Return vs Industry: Insufficient data to determine how LT4 performed against the German Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how LT4 performed against the German Market.

Price Volatility

Is LT4's price volatile compared to industry and market?
LT4 volatility
LT4 Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement7.9%
Market Average Movement5.0%
10% most volatile stocks in DE Market11.5%
10% least volatile stocks in DE Market2.4%

Stable Share Price: LT4's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine LT4's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
2004145Roger Jeffswww.liquidia.com

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion.

Liquidia Corporation Fundamentals Summary

How do Liquidia's earnings and revenue compare to its market cap?
LT4 fundamental statistics
Market cap€854.95m
Earnings (TTM)-€103.46m
Revenue (TTM)€13.69m

62.4x

P/S Ratio

-8.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
LT4 income statement (TTM)
RevenueUS$14.84m
Cost of RevenueUS$4.52m
Gross ProfitUS$10.32m
Other ExpensesUS$122.43m
Earnings-US$112.11m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin69.52%
Net Profit Margin-755.46%
Debt/Equity Ratio137.0%

How did LT4 perform over the long term?

See historical performance and comparison